SEC ownership of Entera Bio Ltd.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001638097.

Comparable stake leader

BIOTECHNOLOGY VALUE FUND L P

Disclosed value leader

BIOTECHNOLOGY VALUE FUND L P

Comparable rows

31/48

Latest evidence

07 Aug 2026

Top shareholders Insider holders Latest transactions
Public ticker
ENTX on Nasdaq
Parsed ownership sources
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
BIOTECHNOLOGY VALUE FUND L P
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
31 of 48
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
BIOTECHNOLOGY VALUE FUND L P
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
07 Aug 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001638097
Issuer location
Jerusalem

Ownership snapshot

Top shareholders of Entera Bio Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
31/48
Latest evidence
07 Aug 2026
13D/G 13F 3/4/5 Lead comparable stake: 10% 17 rows are not safely comparable across share classes. 13D/G row: BIOTECHNOLOGY VALUE FUND L P Showing 1-8 of 48 holder rows.

Quick read

BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 10%.

31 of 48 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership Top 5
BIOTECHNOLOGY VALUE FUND L P 10%
OPKO HEALTH, INC. 8.1%
TCG Crossover GP III, LLC 7.1%
Vivo Opportunity Fund Holdings, L.P. 6.9%
Longitude Capital Partners V, LLC 4.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 48 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
13D/G
10%
$28,593,701
17,225,121 shares
 $0 28 Jul 2026
OPKO HEALTH, INC.
13D/G
13D/G
8.1%
$8,660,281
3,685,226 shares
 $0 16 Mar 2025
TCG Crossover GP III, LLC
13D/G
13D/G
7.1%
$20,343,136
12,254,901 shares
 $0 28 Jul 2026
Vivo Opportunity Fund Holdings, L.P.
13D/G
Vivo Opportunity, LLC
13D/G
6.9%
$19,616,886
11,817,401 shares
 $0 28 Jul 2026
Longitude Capital Partners V, LLC
13D/G
13D/G
4.6%
$13,019,609
7,843,138 shares
 $0 28 Jul 2026
Seven Fleet Capital Management LP
13D/G 13F
Company
13D/G 13F
4.1%
$11,709,471
7,053,898 shares
 $0 28 Jul 2026
Point72 Asset Management, L.P.
13D/G 13F
Company
13D/G 13F
2.6%
$2,271,583
1,183,116 shares
 -$2,915,412 30 Sep 2025
Knoll Capital Management, LLC
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
3.4%
$6,470,066
5,881,879 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$140,882.

Buys
$140,882
Insiders: 5
Sells
$0
Insiders: 0
Net
+$140,882
Shares: +101,500
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 101,500 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 30,000 0 $38,300 $0 +$38,300
6-9 71,500 0 $102,582 $0 +$102,582
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to Entera Bio Ltd.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Knoll Capital Management, LLC
Net 12M change
+$140,882
Latest report
07 Aug 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Knoll Capital Management, LLC 10%+ Owner $5,534,275 Mixed 14 Nov 2024
Miranda Jayne Toledano Chief Executive Officer, Director $1,499,428 +$19,912 +1.3% Median 07 Aug 2026
Gerald M. Lieberman Director $823,723 Mixed 01 Jan 2026
Phillip Schwartz President of R&D, Director $601,336 Mixed 20 Jan 2022
Sean Ellis Director $368,393 +$34,620 +10% Median 07 Aug 2026
Haya Taitel Director $211,106 +$11,100 +5.5% Median 07 Aug 2026
Gregory Burshtein Chief of R&D $209,826 Mixed 07 Aug 2026
Dana Yaacov-Garbeli Chief Financial Officer $190,299 Mixed 07 Aug 2026
Hillel Galitzer Chief Operating Officer $181,558 Mixed 07 Aug 2026
Gerald M. Ostrov Director $180,820 Mixed 01 Jan 2026
Yonatan Malca Director $177,408 Median 07 Aug 2026
Geno J. Germano Director $115,074 +$55,800 +94% Median 07 Aug 2026
Steven D. Rubin Director $60,387 +$19,450 +48% Median 07 Aug 2026
Ramesh Ratan U.S.based CFO $9,900 Mixed 19 Jan 2022
Spiros Jamas Chief Executive Officer $9,900 Mixed 18 Jan 2022
Ron Mayron Director Mixed 01 Jan 2024
Roger Garceau Director Mixed 01 Jan 2024
Arthur C. Santora II Chief Medical Officer Mixed 24 Apr 2023
Leslie Velka Gautam Chief Business Officer Mixed 08 May 2025

Recent insider transactions for Entera Bio Ltd.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Steven D. Rubin ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 127.4% 19,117 34,117 07 Aug 2026 Direct
Steven D. Rubin ENTX Stock Option (right to buy) Award 76,773 43,405 07 Aug 2026 Direct
Yonatan Malca ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 29.5% 22,815 100,231 07 Aug 2026 Direct
Haya Taitel ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 21.1% 20,790 119,269 07 Aug 2026 Direct
Sean Ellis ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 10.6% 20,034 208,132 07 Aug 2026 Direct
Sean Ellis ENTX Stock Option (right to buy) Award 40,000 40,000 07 Aug 2026 Direct
Dana Yaacov-Garbeli ENTX Stock Option (right to buy) Award 140,000 140,000 07 Aug 2026 Direct
Hillel Galitzer ENTX Stock Option (right to buy) Award 200,000 200,000 07 Aug 2026 Direct
Gregory Burshtein ENTX Stock Option (right to buy) Award 180,000 180,000 07 Aug 2026 Direct
Miranda Jayne Toledano ENTX Stock Option (right to buy) Award 700,000 500,000 07 Aug 2026 Direct
Geno J. Germano ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 62.5% 25,014 65,014 07 Aug 2026 Direct
Geno J. Germano ENTX Stock Option (right to buy) Award 93,014 50,000 07 Aug 2026 Direct
Miranda Jayne Toledano ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 98.6% 420,560 847,135 14 Jul 2026 Direct
Hillel Galitzer ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 80.6% 72,993 163,566 07 May 2026 Direct
Dana Yaacov-Garbeli ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 51.6% 58,394 171,441 07 May 2026 By A2Z Counseling Ltd.
Gregory Burshtein ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 86.4% 87,591 189,033 07 May 2026 Direct
Geno J. Germano ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase 100% $26,000 $1.30 20,000 40,000 09 Mar 2026 Direct
Sean Ellis ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase 5.61% $12,300 $1.23 10,000 188,098 05 Mar 2026 Direct
Steven D. Rubin ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase 50% $7,450 $1.49 5,000 15,000 12 Feb 2026 Direct
Haya Taitel ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $11,100 $1.48 7,500 $98,479 10 Feb 2026 Direct
Geno J. Germano ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $29,800 $1.49 20,000 $20,000 10 Feb 2026 Direct
Steven D. Rubin ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $12,000 $1.20 10,000 10,000 09 Feb 2026 Direct
Sean Ellis ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase 11.2% $22,320 $1.24 18,000 178,098 09 Feb 2026 Direct
Haya Taitel ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 40.7% 26,329 90,979 01 Jan 2026 Direct
Haya Taitel ENTX Stock Option (right to buy) Award 33,505 33,505 01 Jan 2026 Direct
Gerald M. Ostrov ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 61.2% 28,721 75,657 01 Jan 2026 Direct
Gerald M. Ostrov ENTX Stock Option (right to buy) Award 33,505 33,505 01 Jan 2026 Direct
Sean Ellis ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 18.8% 25,371 160,098 01 Jan 2026 Direct
Sean Ellis ENTX Stock Option (right to buy) Award 33,505 33,505 01 Jan 2026 Direct
Yonatan Malca ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 63.8% 30,157 77,416 01 Jan 2026 Direct
Yonatan Malca ENTX Stock Option (right to buy) Award 33,505 33,505 01 Jan 2026 Direct
Gerald M. Lieberman ENTX Ordinary Shares, par value NIS 0.0000769 per share Award 12.8% 38,294 338,454 01 Jan 2026 Direct
Gerald M. Lieberman ENTX Stock Option (right to buy) Award 33,505 33,505 01 Jan 2026 Direct
Miranda Jayne Toledano ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase 2.65% $19,912 $1.81 11,000 426,575 29 Dec 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .